Oxidative Stress in Hemodialysis Patients: Pathophysiological Mechanisms, Clinical Consequences and basic Principles of Treatment

Svetlana Antic; Nevena Draginic; Tomislav Nikolic; Nevena Jeremic; Dejan Petrovic

doi:10.2478/sjecr-2019-0008

References

Cozzolino M, Mangano M, Stucchi A, et al. (2018). Cardiovascular disease in dialysis patients. Nephrol Dial Transplant. 33(1), 28–34. DOI: 10.1093/ndt/gfy174.
Open DOI Search in Google Scholar Back to article
Zoccali C, Mallamaci F, Tripepi G. (2004). Novel Cardiovascular Risk Factors in End-Stage Renal Disease. J Am Soc Nephrol. 15(Suppl 1), 77–80. DOI: 10.1097/01.ASN.0000093240.84097.FE.
Open DOI Search in Google Scholar Back to article
Locatelli F, Canaud B, Eckardt K-U, et al. (2003). Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant. 18(7), 1272–80. DOI: 10.1093/ndt/gfg074.
Open DOI Search in Google Scholar Back to article
Descamps-Latscha B, Drüeke T, Witko-Sarsat V. (2001). Dialysis-induced oxidative stress: biological aspects, clinical consequences, and therapy. Semin Dial. 14(3), 793–9. DOI: 10.1046/j.1525-139X.2001.00052.x.
Open DOI Search in Google Scholar Back to article
Liakopoulos V, Roumeliotis S, Gorny X, et al. (2017). Oxidative Stress in Hemodialysis Patients: A Review of the Literature. Oxidative Med Cell Long. 2017: 3081856., DOI: 10.1155/2017/3081856.
Open DOI Search in Google Scholar Back to article
Santoro A, Guadagni G. (2010). Dialysis membrane: from convection to adsorption. Nephrol Dial Transplant. 3(Suppl 1), 36–9. DOI: 10.1093/ndtplus/sfg035.
Open DOI Search in Google Scholar Back to article
Ronco C, Clark W. Hemodialysis membranes. (2018). Nat Rev Nephrol. 14(6), 394–410. DOI: 10.1038/s41581-018-0002-x.
Open DOI Search in Google Scholar Back to article
Wu CC, Chen JS, Wu WM, et al. (2005). Myeloperoxidase serves as a marker of oxidative stress during single hemodialysis session using two different biocompatible dialysis membranes. Nephrol Dial Transplant. 20(6), 1134–9. DOI: 10.1093/ndt/gfh764.
Open DOI Search in Google Scholar Back to article
Ward RA. Ultrapure Dialysate. (2004). Semin Dial. 17(6), 489–97. DOI: 10.1111/j.0894-0959.2004.17617.x.
Open DOI Search in Google Scholar Back to article
Glorieux G, Neirynck N, Veys N, et al. (2012). Dialysis water and fluid purity: more than endotoxin. Nephrol Dial Transplant. 27(11), 4010–21. DOI: 10.1093/ndt/gfs306.
Open DOI Search in Google Scholar Back to article
Aziz MA, Majeed GH, Diab KS, et al. (2016). The association of oxidant-antioxidant status in patients with chronic renal failure. Ren Fail. 38(1), 20–6. DOI: 10.3109/0886022X.2015.1103654.
Open DOI Search in Google Scholar Back to article
Handelman GJ. (2007). Vitamin C deficiency in dialysis patients - are we perceiving the tip of an iceberg? Nephrol Dial Transplant. 22(2), 328–31. DOI: 10.1093/ndt/gfl534.
Open DOI Search in Google Scholar Back to article
Zalba G, Fortuño A, Diez J. (2006). Oxidative stress and atherosclerosis in early chronic kidney disease. Nephrol Dial Transplant. 21(10), 2686–90. DOI: 10.1093/ndt/gfl398.
Open DOI Search in Google Scholar Back to article
Massy ZA. (2000). Importance of homocystein, lipoprotein (a) and non-classical cardiovascular risk factors (fibrinogen, and advanced glycation end-products) for atherogenesis in uraemic patients. Nephrol Dial Transplant. 15(Suppl 5), 81–91. DOI: 10.1093/ndt/15.suppl_5.81.
Open DOI Search in Google Scholar Back to article
Culleton BF, Bostom AG. (2000). Hyperhomocysteinemia in chronic renal disease. In: Cardiovascular Disease in End-stage Renal Failure. Loscalzo J, London GM, (eds). The Oxford University Press, New York, 2000: 211–28.
Search in Google Scholar Back to article
Kielstein JT, Frölich JC, Haller H, et al. (2001). ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patient with renal disease? Nephrol Dial Transplant. 16(9), 1742–5. DOI: 10.1093/ndt/16.9.1742.
Open DOI Search in Google Scholar Back to article
Lacson E, Levin NW. (2004). C-Reactive Protein and End-Stage Renal Disease. Semin Dial. 17(6), 438–48. DOI: 10.1111/j.0894-0959.2004.17604.x.
Open DOI Search in Google Scholar Back to article
Petrović D, Obrenović R, Poskurica M, i ost. (2007). Povezanost C-reaktivnog proteina sa ehokardiografskim parametrima hipertrofije i ishemijske bolesti srca u bolesnika koji se leče ponavljanim hemodijalizama. Med Pregl. LX (Suppl 2), 160–4.
Search in Google Scholar Back to article
Akchurin OM, Kaskel F. (2015). Update on Inflammation in Chronic Kidney Disease. Blood Purif. 39(1), 84–92. DOI: 10.1159/000368940.
Open DOI Search in Google Scholar Back to article
Koenig W. (2003). C-reactive protein and cardiovascular risk: an update on what is going on in cardiology. Nephrol Dial Transplant. 18(6), 1039–41. DOI: 10.1093/ndt/gfg103.
Open DOI Search in Google Scholar Back to article
Kanbay M, Perazella MA, Kasapoglu B, et al. (2010). Erythropoiesis Stimulatory Agent-Resistant Anemia in Dialysis Patients: Review of Causes and Management. Blood Purif. 29(1), 1–12. DOI: 10.1159/000245041.
Open DOI Search in Google Scholar Back to article
Locatelli F, Canaud B, Eckardt KU, et al. (2003). Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant. 18(7), 1272–80. DOI: 10.1093/ndt/gfg074.
Open DOI Search in Google Scholar Back to article
Liakopoulos V, Roumeliotis S, Zarogiannis S, et al. (2019). Oxidative stress in hemodialysis: Causative mechanisms, clinical implications, and possible therapeutic interventions. Semin Dial. 32(1), 58–71. DOI: 10.1111/sdi.12745.
Open DOI Search in Google Scholar Back to article
Liakopoulos V, Roumeliotis S, Bozikas A, et al. (2019). Antioxidant Supplementation in Renal Replacement Therapy Patients: Is There Evidence? Oxidative Med Cell Long. 2019, Article ID 9109473, 23 pages. DOI: 10.1155/2019/9109473.
Open DOI Search in Google Scholar Back to article
Zhang KY, Zuo L. (2014). Vitamin C supplementation in patients on maintenance dialysis. W J Clin Urol. 3(3), 344–50. DOI: 10.5410/wjcu.v3.i3.344.
Open DOI Search in Google Scholar Back to article
Coombes JS, Fassett RG. (2012). Antioxidant therapy in hemodialysis patients: a systematic review. Kidney Int. 81(3), 233–46. DOI: 10.1038/ki.2011.341.
Open DOI Search in Google Scholar Back to article
Gokbel H, Atalay H, Okudan N, et al (2011). Coenzyme Q10 and its Relation with Oxidant and Antioxidant System Markers in Patients with End-Stage Renal Disease. Ren Fail. 33(7), 677–81. DOI: 10.3109/0886022X.2011.589941.
Open DOI Search in Google Scholar Back to article
Den Hoedt CH, Bots ML, Grooteman MPC, et al. (2014). Online hemodiafiltration reduces systemic inflammation compared to low-flux hemodialysis. Kidney Int 86(2), 423–32. DOI: 10.1038/ki.2014.9.
Open DOI Search in Google Scholar Back to article
Panichi V, Scatena A, Rosati A, et al. (2015). High-volume online hemodiafiltration improves erythropoiesisstimulating agents (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study. Nephrol Dial Transplant. 30(4): 682–9. DOI: 10.1093/ndt/gfu345.
Open DOI Search in Google Scholar Back to article
Tarng DC, Huang TP, Liu TY, et al. (2000). Effect of vitamin E-bonded membrane on the 8-hydroxy 2,-deoxyguanosine level in leukocyte DNA of hemodialysis patients. Kidney Int. 58(2), 790–9. DOI: 10.1046/j.1523-1755.2000.00228.x.
Open DOI Search in Google Scholar Back to article
Andrulli S, Di Fillipo S, Manzoni C, et al. (2010). Effect of synthetic vitamin E-bonded membrane on responsiveness to erythropoiesis-stimulating agents in hemodialysis patients: a pilot study. Nephron Clin Pract 115(1), 82–9. DOI: 10.1159/000294281.
Open DOI Search in Google Scholar Back to article
Panagiotou A, Nalesso F, Zanella M, et al. Antioxidant Dialytic Approach with Vitamin E-Coated Membranes. In: Ronco C, Rosner MH. Eds. Hemodialysis: New Methods and Future Technology. Contrib Nephrol. Basel, Karger, 2011; 171: 101–6.
Search in Google Scholar Back to article
Panichi V, Rosati A, Paoletti S, et al. (2011). A vitamin E-coated polysulphone membrane reduces serum levels of inflammatory markers and resistance to erythropoietin-stimulating agents in hemodialysis patients: results of a randomized cross-over multicenter trial. Blood Purif. 32(1), 7–14. DOI: 10.1159/000321369.
Open DOI Search in Google Scholar Back to article
Yang SK, Xiao L, Xu B, et al. (2014). Effects of vitamin E-coated dialyzer on oxidative stress and inflammation status in hemodialysis patients: a systematic review and meta-analysis. Ren Fail. 36(5), 722–31. DOI: 10.3109/0886022X.2014.890858.
Open DOI Search in Google Scholar Back to article
Yamadera S, Nakamura Y, Inagaki M, et al. (2017). Vitamin E-Coated Dialyzer Inhibits Oxidative Stress. Blood Purif. 44(4), 288–93. DOI: 10.1159/000478971.
Open DOI Search in Google Scholar Back to article
D’Arrigo G, Baggetta R, Tripepi G, et al. (2017). Effects of vitamin E-Coated versus Conventiional Membranes in Chronic Hemodialysis Patients: A Systemic Review and Meta-Analysis. Blood Purif. 43(1–3), 101–22. DOI: 10.1159/000453444.
Open DOI Search in Google Scholar Back to article
Locatelli F, Andrulli S, Vigano SM, et al. (2017). Evaluation of the Impact of a New Synthetic Vitamin EBonded Membrane on the Hypo-Responsiveness to the Erythropoietin Therapy in Hemodialysis Patients: A Multicenter Study. Blood Purif. 43(4), 338–45. DOI: 10.1159/000453442.
Open DOI Search in Google Scholar Back to article
Fishbane S, Singh AK, Cournoyer SH, et al. (2015). Ferric pyrophosphate citrate (Triferic^™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients. Nephrol Dial Transplant. 30(12), 2019–26. DOI: 10.1093/ndt/gfv277.
Open DOI Search in Google Scholar Back to article
Gupta A, Lin V, Guss C, et al. (2015). Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients. Kidney Int. 88(5), 1187–94. DOI: 10.1038/ki.2015.203.
Open DOI Search in Google Scholar Back to article
Shah HH, Hazzan AD, Fishbane S. (2016). Ferric Pyrophosphate Citrate: A Novel Iron Replacement Agent in Patients Undergoing Hemodialys. Semin Nephrol. 36(2), 124–9. DOI: 10.1016/j.semnephrol.2016.02.007.
Open DOI Search in Google Scholar Back to article
Fishbane S, Shah HH. (2017). Ferric pyrophosphate citrate as an iron replacement agent for patients receiving hemodialysis. Hemodialysis Int. 21(Suppl 1), 104–9. DOI: 10.1111/hdi.12554.
Open DOI Search in Google Scholar Back to article

Oxidative Stress in Hemodialysis Patients: Pathophysiological Mechanisms, Clinical Consequences and basic Principles of Treatment

References

Paradigm

My account